Monday, February 26, 2024
BestWooCommerceThemeBuilttoBoostSales-728x90

Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy – British Journal of Cancer


  • Wu C, Li M, Meng H, Liu Y, Niu W, Zhou Y, et al. Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci. 2019;62:640–7.

    Article 
    PubMed 

    Google Scholar
     

  • Heil J, Kuerer HM, Pfob A, Rauch G, Sinn HP, Golatta M, et al. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol Off J Eur Soc Med Oncol. 2020;31:61–71.

    Article 
    CAS 

    Google Scholar
     

  • Spring LM, Bar Y, Isakoff SJ. The evolving role of neoadjuvant therapy for operable breast cancer. J Natl Compr Canc Netw. 2022;20:723–34.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Derouane F, van Marcke C, Berliere M, Gerday A, Fellah L, Leconte I, et al. Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine. Cancers (Basel). 2022;14:3876.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13–21.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Schaefgen B, Mati M, Sinn HP, Golatta M, Stieber A, Rauch G, et al. Can routine imaging after neoadjuvant chemotherapy in breast cancer predict pathologic complete response? Ann Surg Oncol. 2016;23:789–95.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Members of Breast Cancer Expert Panel on, C. Expert panel consensus on pathological diagnosis of breast cancer with neoadjuvant therapy, the 2020 version. Zhonghua Bing Li Xue Za Zhi. 2020;49:296–304.


    Google Scholar
     

  • Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (Lond, Engl). 2014;384:164–72.

    Article 

    Google Scholar
     

  • Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021;375:e066381.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tasoulis MK, Lee HB, Yang W, Pope R, Krishnamurthy S, Kim SY, et al. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer. JAMA Surg. 2020;155:e204103.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Goto W, Kashiwagi S, Takada K, Asano Y, Takahashi K, Fujita H, et al. Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy. J Transl Med. 2018;16:307.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Takaoka M, OS, Ikejiri H, Shidahara T, Miyoshi Y, Takahashi M, et al. Pathological complete response patients after neoadjuvant chemotherapy in breast cancer. Acta Med Okayama. 2022;76:105–11.

    CAS 
    PubMed 

    Google Scholar
     

  • Zhou Z, Cong L, Cong X. Patient-derived organoids in precision medicine: drug screening, organoid-on-a-chip and living organoid biobank. Front Oncol. 2021;11:762184.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell. 2020;180:188–204.e122.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kim M, Mun H, Sung CO, Cho EJ, Jeon HJ, Chun SM, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019;10:3991.

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Li M, Izpisua Belmonte JC. Organoids—preclinical models of human disease. N Engl J Med. 2019;380:569–79.

    Article 
    PubMed 

    Google Scholar
     

  • Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172:373–86.e310.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Yan HHN, Siu HC, Law S, Ho SL, Yue SSK, Tsui WY, et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell. 2018;23:882–97.e811.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ganesh K, Wu C, O’Rourke KP, Szeglin BC, Zheng Y, Sauve CG, et al. A rectal cancer organoid platform to study individual responses to chemoradiation. Nat Med. 2019;25:1607–14.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920–6.

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wang HM, Zhang CY, Peng KC, Chen ZX, Su JW, Li YF, et al. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study. Cell Rep. Med. 2023;4:100911.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Xu R, Zhou X, Wang S, Trinkle C. Tumor organoid models in precision medicine and investigating cancer-stromal interactions. Pharm Ther. 2021;218:107668.

    Article 
    CAS 

    Google Scholar
     

  • Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147–59.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12:320–7.

    Article 
    PubMed 

    Google Scholar
     

  • Hagenaars SC, de Groot S, Cohen D, Dekker TJA, Charehbili A, Meershoek-Klein Kranenbarg E, et al. Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer. Int J Cancer. 2021;149:1181–8.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Vasmel JE, Vreuls CPH, Manson QF, Charaghvandi RK, van Gorp J, van Leeuwen AMG, et al. Tumor-infiltrating lymphocytes in low-risk patients with breast cancer treated with single-dose preoperative partial breast irradiation. Int J Radiat Oncol Biol Phys. 2021;109:1325–31.

    Article 
    PubMed 

    Google Scholar
     

  • Nie JH, Yang T, Li H, Ye HS, Zhong GQ, Li TT, et al. Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target. J Bone Oncol. 2021;30:100391.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ye HS, Gao HF, Li H, Nie JH, Li TT, Lu MD, et al. Higher efficacy of resveratrol against advanced breast cancer organoids: a comparison with that of clinically relevant drugs. Phytother Res. 2022;36:3313–24.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Xiong L, Nie JH, Lin XM, Wu JB, Chen Z, Xu B, et al. Biological implications of PTEN upregulation and altered sodium/iodide symporter intracellular distribution in resveratrol-suppressed anaplastic thyroid cancer cells. J Cancer. 2020;11:6883–91.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Varela CL, Amaral C, Tavares da Silva E, Lopes A, Correia-da-Silva G, Carvalho RA, et al. Exemestane metabolites: synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line. Eur J Med Chem. 2014;87:336–45.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–804.

    Article 

    Google Scholar
     

  • Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–81.

    Article 
    PubMed 

    Google Scholar
     

  • Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst. 2013;105:321–33.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Loibl S, Denkert C. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017;35:1029–30.

    Article 
    PubMed 

    Google Scholar
     

  • Chen P, Zhang X, Ding R, Yang L, Lyu X, Zeng J, et al. Patient-derived organoids can guide personalized-therapies for patients with advanced breast cancer. Adv Sci (Weinh). 2021;8:e2101176.

    Article 
    PubMed 

    Google Scholar
     

  • Pan B, Li X, Zhao D, Li N, Wang K, Li M, et al. Optimizing individualized treatment strategy based on breast cancer organoid model. Clin Transl Med. 2021;11:e380.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Guillen KP, Fujita M, Butterfield AJ, Scherer SD, Bailey MH, Chu Z, et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer. 2022;3:232–50.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pelizzari G, Gerratana L, Basile D, Fanotto V, Bartoletti M, Liguori A, et al. Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. Cancer Treat Rev. 2019;72:7–14.

    Article 
    PubMed 

    Google Scholar
     

  • Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Vrancken Peeters M, et al. Prognostic value of residual disease after neoadjuvant therapy in HER2-positive breast cancer evaluated by residual cancer burden, neoadjuvant response Index, and Neo-Bioscore. Clin Cancer Res. 2019;25:4985–92.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Li L, Knutsdottir H, Hui K, Weiss MJ, He J, Philosophe B, et al. Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. JCI Insight. 2019;4:e121490.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Huang L, Bockorny B, Paul I, Akshinthala D, Frappart PO, Gandarilla O, et al. PDX-derived organoids model in vivo drug response and secrete biomarkers. JCI Insight. 2020;5:e135544.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tiriac H, Belleau P, Engle DD, Plenker D, Deschenes A, Somerville TDD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8:1112–29.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tang Y, Wang T, Hu Y, Ji H, Yan B, Hu X, et al. Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer. iScience. 2023;26:107116.

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Veninga V, Voest EE. Tumor organoids: opportunities and challenges to guide precision medicine. Cancer Cell. 2021;39:1190–201.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Shiihara M, Ishikawa T, Saiki Y, Omori Y, Hirose K, Fukushige S, et al. Development of a system combining comprehensive genotyping and organoid cultures for identifying and testing genotype-oriented personalised medicine for pancreatobiliary cancers. Eur J Cancer. 2021;148:239–50.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Donzelli S, Cioce M, Sacconi A, Zanconato F, Daralioti T, Goeman F, et al. A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions. Mol Cancer. 2022;21:152.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 2018;173:515–28.e517.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Vaishampayan UN, Burger AM, Sausville EA, Heilbrun LK, Li J, Horiba MN, et al. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of Sorafenib and Tanespimycin. Clin Cancer Res. 2010;16:3795–804.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     



  • Source link

    Related Articles

    Leave a Reply

    [td_block_social_counter facebook="beingmedicos1" twitter="being_medicos" youtube="beingmedicosgroup" style="style8 td-social-boxed td-social-font-icons" tdc_css="eyJhbGwiOnsibWFyZ2luLWJvdHRvbSI6IjM4IiwiZGlzcGxheSI6IiJ9LCJwb3J0cmFpdCI6eyJtYXJnaW4tYm90dG9tIjoiMzAiLCJkaXNwbGF5IjoiIn0sInBvcnRyYWl0X21heF93aWR0aCI6MTAxOCwicG9ydHJhaXRfbWluX3dpZHRoIjo3Njh9" custom_title="Stay Connected" block_template_id="td_block_template_8" f_header_font_family="712" f_header_font_transform="uppercase" f_header_font_weight="500" f_header_font_size="17" border_color="#dd3333"]
    - Advertisement -spot_img

    Latest Articles